Categories
HIV associated nephropathy natural history, complications and prognosis
From Wikidoc - Reading time: 3 min
|
HIV associated nephropathy Microchapters |
|
Differentiating HIV associated nephropathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
HIV associated nephropathy natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of HIV associated nephropathy natural history, complications and prognosis |
|
FDA on HIV associated nephropathy natural history, complications and prognosis |
|
CDC on HIV associated nephropathy natural history, complications and prognosis |
|
HIV associated nephropathy natural history, complications and prognosis in the news |
|
Blogs on HIV associated nephropathy natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2];Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD[3]Krzysztof Wierzbicki M.D. [4]
Overview[edit | edit source]
HIV-associated nephropathy (HIVAN) will progress to end stage renal disease (ESRD) in a few weeks to months without treatment. However, early diagnosis and treatment has shown better outcome.
Natural History[edit | edit source]
- If left untreated, HIV-associated nephropathy (HIVAN) will progress to end stage renal disease (ESRD) in a few weeks to months.[1]
- Treatment with cART has shown 60% reduction in the developement of HIVAN.[1]
- Treatment with cART has shown 38% slowing in the progression of HIVAN towards ESRD.[1]
- Early diagnosis and Immediate treatment has shown better outcome.[1]
Complications[edit | edit source]
Possible complications that are associated with HIV-associated nephropathy include:
Prognosis[edit | edit source]
- Before the advent of cART therapy, the prognosis of HIV-associated nephropathy was fatal. The mortality rate during this time was 100% within 6 months.[1]
- Today, the prognosis of HIVAN with the availability of cART therapy still remains grim,[1] however, treatment with cART has increased renal survival rate.[2]
- Early diagnosis and Immediate treatment has shown better outcome.[1]
- Treatment with cART has shown 60% reduction in the developement of HIVAN.[1]
- Treatment with cART has shown 38% slowing in the progression of HIVAN towards ESRD.[1]
- The current first and second year survival rate of HIV-associated nephropathy is estimated to be around 63% and 43% respectively, with the use of HAART therapy.[3]
- Several factors have been associated with increased risk of progression of kidney disease in patients with HIVAN, which include:[4]
- Low CD4 count
- High viral load
- Proteinuria (high-grade)
- APOL1 polymorphism
- Comorbidities (hypertension and diabetes)
References[edit | edit source]
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 Atta MG, Lucas GM, Fine DM (2008). "HIV-associated nephropathy: epidemiology, pathogenesis, diagnosis and management". Expert Rev Anti Infect Ther. 6 (3): 365–71. doi:10.1586/14787210.6.3.365. PMID 18588500.
- ↑ Atta MG, Fine DM, Kirk GD, Mehta SH, Moore RD, Lucas GM (2007). "Survival during renal replacement therapy among African Americans infected with HIV type 1 in urban Baltimore, Maryland". Clin Infect Dis. 45 (12): 1625–32. doi:10.1086/523728. PMC 4096866. PMID 18190325.
- ↑ Atta MG, Choi MJ, Longenecker JC, Haymart M, Wu J, Nagajothi N; et al. (2005). "Nephrotic range proteinuria and CD4 count as noninvasive indicators of HIV-associated nephropathy". Am J Med. 118 (11): 1288. doi:10.1016/j.amjmed.2005.05.027. PMID 16271919.
- ↑ Palau L, Menez S, Rodriguez-Sanchez J, Novick T, Delsante M, McMahon BA; et al. (2018). "HIV-associated nephropathy: links, risks and management". HIV AIDS (Auckl). 10: 73–81. doi:10.2147/HIV.S141978. PMC 5975615. PMID 29872351.
EncycloReader
is supported by the 
KSF